GTHP
Guided Therapeutics, Inc.0.2500
-0.0200-7.41%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
20.90MP/E (TTM)
-Basic EPS (TTM)
-0.05Dividend Yield
0%Recent Filings
10-Q
Q3 FY2025 results
Guided Therapeutics posted Q3 sales of $60K from LuViva devices, up from zero y/y, driving gross profit of $35K while operating loss narrowed to $485K from $561K y/y. QTD revenue totaled $177K, +29x y/y, but YTD operating loss widened to $1.7M from $1.6M as G&A jumped on $270K warrant comp to the CEO. Cash dwindled to $87K amid $777K ops burn; debt mix includes $1.1M convertible notes in default at 18% and $411K short-term convertibles. Debt conversions added $138K extinguishment hit. Stockholders' deficit sits at $5.6M. FDA trial data looks solid. Regulatory delays loom.
10-Q
Q2 FY2025 results
Guided Therapeutics posted Q2 revenue of $117K from device and disposable sales, up from nil a year ago but flat sequentially, with gross profit at $79K yielding a 67.5% margin. Operating loss widened to $763K y/y from $655K, driven by higher general and administrative costs including $270K in stock-based compensation, while R&D and sales expenses fell. Net loss hit $811K, or $0.01 per diluted share on 78.8M shares, matching last year but up q/q; the gap from operating loss stems from $157K interest expense. Cash dipped to $185K amid $500K operating burn, offset by $297K from financing including notes and a $205K private placement, leaving $6.4M total debt with key maturities in 2026 and revolver availability undisclosed. No M&A or impairments noted. Non-GAAP metrics not disclosed in the 10-Q. Competition in medical devices poses ongoing risks to market adoption.
10-Q
Q1 FY2025 results
Guided Therapeutics posted a Q1 net loss of $427K, up 6% y/y from $402K, driven by higher R&D costs for clinical trials while sales stayed negligible at zero. Operating expenses climbed 14% y/y to $414K, mainly from sponsored research, yet the company trimmed deferred revenue by $179K and recognized $180K in other income from a China partner agreement. Cash dwindled to $115K from $388K at year-end, with $331K used in operations offset by $205K from a private placement; total debt sits at $6M including $1.1M in defaulted convertible notes at 18% interest. No free cash flow disclosed in the 10-Q. Preferred dividends persist at $36K. Regulatory hurdles loom large.
10-K
FY2024 results
Guided Therapeutics wrapped FY2024 with a $2.4 million net loss, narrower than 2023's $3.4 million, amid minimal revenue of $7,000 from LuViva device sales—down sharply from $98,000—while deferred revenue swelled to $849,000 awaiting shipments tied to China's NMPA review. Q4 saw R&D expenses surge 130% year-over-year to $526,000, driven by clinical trial costs for U.S. FDA approval, where 320 of 400 patients are enrolled with completion eyed for 2025; meanwhile, sales and marketing held steady at $287,000 as international distributors shoulder local efforts. General and administrative costs plunged 57% to $1.3 million, reflecting fewer stock-based awards and consultant fees. Liquidity remains tight at $388,000 cash against $6.3 million debt, including $1.1 million in defaulted convertibles, with no dividends or buybacks but $835,000 raised via private placements. NMPA approval, filed October 2024, could unlock $2.45 million in orders from China by mid-2025. Yet regulatory delays in China or the U.S. could stall quarterly momentum.
8-K
Guided Therapeutics secures $535K funding
Guided Therapeutics raised $535,000 on December 18, 2024, via a private placement, selling 4,115,386 common shares and warrants at $0.13 each to institutional investors, including board member John Imhoff. Warrants, exercisable immediately at $0.18 per share, expire in four years. Funds target working capital, manufacturing for international orders, FDA studies, and product commercialization in China. Dilution hits shareholders hard.
CV
CapsoVision, Inc.
12.00-1.78
LUCD
Lucid Diagnostics Inc.
1.12+0.01
NVCR
NovoCure Limited
12.93-0.04
PAVM
PAVmed Inc.
0.31-0.01
PHG
Koninklijke Philips N.V. NY Reg
26.53+0.07
RDGL
Vivos Inc.
0.07-0.00
RPID
Rapid Micro Biosystems, Inc.
3.52+0.05
RXST
RxSight, Inc.
12.76+0.24
TOVX
Theriva Biologics, Inc.
0.21+0.01
VVOS
Vivos Therapeutics, Inc.
2.02+0.00